Technology And Equipment Tenders

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Dabigatran, Atc B01ae07 for the Period September 1St, 2023 - August 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Glecaprevir and Pibrentasvir, Atc J05ap57 for the Period 09/01/2023 - 08/31/2025

Conclusion of a Non-Exclusive Framework Contract for Test Engineering Services in the Open House Procedure of the Rhineland Branch, Published in 2023

Oh-Biologika-2023-21 - Teriparatids

Open House Drug Rebate Contracts Nilotinib, Atc L01ea03

Finished Medicinal Product Called Itulazax (Atc: V01aa05 - Tree Pollen)

Medicines with the Active Ingredient Combination Tramadol and Paracetamol (Atc: N02aj13)

Medicines Containing the Active Ingredient Tolvaptan (G04bx21)

Open House Drug Discount Agreements Amifampridine, Atc N07xx05

Medicines Containing the Active Ingredient Tolvaptan (Atc: C03xa01)